Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente

Translated title of the contribution: Felbamate: A new evaluation in refractory epileptic patients

L. M. Specchio, A. La Neve, A. Spinelli, G. Boero, N. Specchio

Research output: Contribution to journalArticlepeer-review


FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.

Translated title of the contributionFelbamate: A new evaluation in refractory epileptic patients
Original languageItalian
Pages (from-to)313-315
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number106-107
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Felbamate: A new evaluation in refractory epileptic patients'. Together they form a unique fingerprint.

Cite this